News ReleaseThis Company Is Taking An Innovative, Non-Opioid Approach To Pain Management For Pancreatic Cancer
Autonomix Medical, Inc.
By Austin DeNoce, Benzinga Pancreatic cancer is one of the most aggressive and painful forms of cancer, often leaving patients with limited options for effective pain management. Traditional treatments like opioids and nerve blocks offer only temporary relief, and their side effects can further diminish the quality of life. This underscores the urgent need for innovative solutions that can provide sustainable pain relief for those battling this debilitating disease. Autonomix Medical (NASDAQ: AMIX) is working to address this critical gap with a novel, non-opioid approach designed to significantly reduce pain in pancreatic cancer patients. The company recently shared promising preliminary data from its ongoing human clinical trial, showcasing the potential of its precision nerve-targeted treatment. This minimally invasive method aims to deliver lasting pain relief, offering hope to patients who have struggled to find effective alternatives to around-the-clock opioids. “We are encouraged by the significant, sustained pain reduction demonstrated from the lead-in patients in our ongoing first-in-human trial. These are very sick individuals, who up until this point primarily relied on opioids to help mitigate their pain, which our baseline data shows were not effective,” said Autonomix CEO Brad Hauser. Overview Of Preliminary Results In early September, Autonomix announced positive outcomes from its proof-of-concept trial. The results indicated that 60% of patients in the initial cohort experienced a substantial reduction in pain. Using the Visual Analog Scale (VAS), patients reported a dramatic drop in pain scores from an average of 8.0 to just 1.33 within 4 to 6 weeks post-procedure — an 83% reduction. Significantly, patients in the responder group felt pain relief as early as one day after the procedure, highlighting the potential for rapid and meaningful impact. The trial also identified a key factor that may factor in treatment success: the access point used during the procedure. Patients treated through femoral access showed significant improvements, while those with brachial access did not. These findings suggest that the method of delivery may play a crucial role in optimizing outcomes. Innovative Technology Behind The Treatment Autonomix reports that its groundbreaking technology employs a catheter-based microchip sensing array capable of detecting and differentiating nerve signals with extraordinary precision – up to 3,000 times greater than existing methods. The company says this advanced platform not only identifies overactive nerve signals but also targets them with radiofrequency (RF) ablation, providing precise pain relief without the common drawbacks of conventional treatments. Looking Ahead: Expanding The Possibilities The trial is expected to complete patient enrollment by the end of 2024, with plans to incorporate additional biomarkers to refine the correlation between nerve ablation and pain relief. The success of this trial could pave the way for a new standard in pain management, extending beyond pancreatic cancer to other conditions characterized by severe nerve-related pain. A Potential Game-Changer, Non-Opioid Approach In Pain Therapy Autonomix Medical could be poised to help revolutionize pain management, not only for pancreatic cancer patients but for a broader range of chronic pain conditions. As their technology evolves and clinical trials progress, the company says its approach could transform the landscape of pain therapy, offering hope and improved quality of life to countless individuals. By developing cutting-edge solutions, Autonomix is not just addressing a critical unmet need but also potentially setting the stage for a new era in precision pain management. With the potential to impact a significant segment of the multi-billion-dollar pain management market, this breakthrough could mark a turning point in the way we treat pain in complex medical conditions. Featured photo by Ousa Chea from Unsplash. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC autonomix@jtcir.com Company Website https://autonomix.com/
October 03, 2024 08:35 AM Eastern Daylight Time
Image
